2012 Updated Consensus Guidelines for the Management of Abnormal Cervical Cancer Screening Tests and Cancer Precursors

@article{Massad20132012UC,
  title={2012 Updated Consensus Guidelines for the Management of Abnormal Cervical Cancer Screening Tests and Cancer Precursors},
  author={Leslie Stewart Massad and Mark H. Einstein and Warner K. Huh and Hormuzd A. Katki and Walter Kinney and Mark Schiffman and Diane H. Solomon and Nicolas Wentzensen and Herschel W. Lawson},
  journal={Journal of Lower Genital Tract Disease},
  year={2013},
  volume={17},
  pages={S1–S27}
}
ABSTRACT A group of 47 experts representing 23 professional societies, national and international health organizations, and federal agencies met in Bethesda, MD, September 14–15, 2012, to revise the 2006 American Society for Colposcopy and Cervical Pathology Consensus Guidelines. The group’s goal was to provide revised evidence-based consensus guidelines for managing women with abnormal cervical cancer screening tests, cervical intraepithelial neoplasia (CIN) and adenocarcinoma in situ (AIS… 
Developing guidelines for cervical cancer prevention in the face of diagnostic complexity.
  • L. Massad
  • Medicine
    Journal of the National Comprehensive Cancer Network : JNCCN
  • 2014
TLDR
New guidelines provide guidance for the conservative management of young women, for women with unsatisfactory Papanicolaou tests and tests with limited transformation zone component, and for the incorporation of HPV 16/18 genotyping results into management decisions.
Risk Estimates Supporting the 2019 ASCCP Risk-Based Management Consensus Guidelines
TLDR
The key risk estimates supporting guidelines are presented and explained by presenting and explaining the risk estimates that supported the guidelines, and the immediate and 5-year risks of CIN 3+ used to decide clinical management are shown.
2012 updated consensus guidelines for the management of abnormal cervical cancer screening tests and cancer precursors.
To the Editor: I have a question about the article by Massad et al in the April 2013 issue of the journal. On page 840, the authors state, "For women aged 21–24 years with CIN 1 after ASC-H or HSIL
Role of Screening History in Clinical Meaning and Optimal Management of Positive Cervical Screening Results.
TLDR
Following one or more sequential antecedent, documented negative co-tests or HPV tests, women with HPV-positive ASC-US or low-grade squamous intraepithelial lesion might have sufficiently low CIN3+ risk that they do not need colposcopy referral and might instead undergo 6-12-month surveillance for evidence of higher risk before being referred to colposcop.
Screening History Among Women with Invasive Cervical Cancer in an Academic Medical Center: Will We Miss Cancers Following Updated Guidelines?
OBJECTIVE Updated guidelines for the screening and management of cervical cancer in the United States recommend starting Papanicolaou (Pap) testing at age 21 and screening less frequently with less
Cervical cancer screening research in the PROSPR I consortium: Rationale, methods and baseline findings from a US cohort
TLDR
Cervical PROSPR I makes available high‐quality, multilevel, longitudinal screening process data from a large and diverse cohort of women to evaluate and improve the effectiveness of US cervical cancer screening delivery.
Current Cervical Carcinoma Screening Guidelines
TLDR
Screening techniques and current recommendations for cervical cancer screening and human papilloma virus (HPV) testing are reviewed, as well as possible future screening strategies.
NEW CERVICAL CANCER SCREENING GUIDELINES ON BOTH SIDES OF THE ATLANTIC
TLDR
This paper compares the recommendations concerning the cervical cancer screening tools proposed by the most influential agencies and scientific societies in the last 3 years and concludes that HPV tests can be used as the primary screening test in patients starting from 30 years of age.
Cervical cancer screening: evidence behind the guidelines.
TLDR
Evidence regarding primary HPV testing as well as postvaccine-based screening strategies will be reviewed, and evidence that has led to the current evidence-based guidelines are focused on.
Discussing Cervical Cancer Screening Options: Outcomes to Guide Conversations Between Patients and Providers
TLDR
A Markov decision model was constructed using estimates of the natural history of HPV and cervical neoplasia to estimate outcomes of screening strategies recommended for women at age 30 and resulted in substantially lower cancer and cancer death rates compared with no screening.
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 134 REFERENCES
2006 Consensus Guidelines for the Management of Women With Abnormal Cervical Screening Tests
TLDR
The 2006 Consensus Guidelines reflect recent data from large clinical trials and advances in technology and are designed to assist clinicians of all subspecialties in managing women with abnormal cervical cancer screening test results.
2006 consensus guidelines for the management of women with cervical intraepithelial neoplasia or adenocarcinoma in situ.
A group of 146 experts representing 29 organizations and professional societies met Sept. 18-19, 2006, in Bethesda, MD, to develop revised evidence-based, consensus guidelines for managing women with
2006 Consensus Guidelines for the Management of Women With Cervical Intraepithelial Neoplasia or Adenocarcinoma In Situ
Objective. To provide updated consensus guidelines for the management of women with cervical intraepithelial neoplasia (CIN) or adenocarcinoma in situ (AIS). Participants. A group of 146 experts
Practice Improvement in Cervical Screening and Management (PICSM): Symposium on Management of Cervical Abnormalities in Adolescents and Young Women
TLDR
9 presentations were presented at a symposium with the primary goal of identifying strategies to increase the adoption of evidence based consensus guidelines for cervical cancer screening and the management of abnormal cervical cytology and histology in adolescents and young women.
2001 Consensus Guidelines for the management of women with cervical cytological abnormalities
TLDR
Management of women with atypical squamous cells (ASC) depends on whether the Papanicolaou test is subcategorized as of undetermined significance (ASC-US) or as cannot exclude high-grade squamous intraepithelial lesion (HSIL) (asc-H).
Benchmarking CIN 3+ Risk as the Basis for Incorporating HPV and Pap Cotesting into Cervical Screening and Management Guidelines
TLDR
Using the principle of “equal management of equal risks,” benchmarking to implicit risk thresholds based on Pap-alone can be used to achieve safe and consistent incorporation of cotesting.
American Cancer Society, American Society for Colposcopy and Cervical Pathology, and American Society for Clinical Pathology screening guidelines for the prevention and early detection of cervical cancer
TLDR
An update to the ACS guideline regarding screening for the early detection of cervical precancerous lesions and cancer is presented, addressing age‐appropriate screening strategies, including the use of cytology and high‐risk human papillomavirus (HPV) testing.
Lessons From Practice: Risk of CIN 3 or Cancer Associated With an LSIL or HPV-Positive ASC-US Screening Result in Women Aged 21 to 24
TLDR
The risk of cervical intraepithelial neoplasia 3 and cancer is low enough that management of women aged 21 to 24 with ASC-US and LSIL smears without immediate colposcopy should be considered, as is currently recommended for women aged 20 and younger.
Screening for Cervical Cancer: U.S. Preventive Services Task Force Recommendation Statement
  • V. Moyer
  • Medicine
    Annals of Internal Medicine
  • 2012
TLDR
New evidence on the comparative test performance of liquid-based cytology and the benefits and harms of human papillomavirus testing as a stand-alone test or in combination with cytology is reviewed.
Cervical cancer risk for women undergoing concurrent testing for human papillomavirus and cervical cytology: a population-based study in routine clinical practice.
TLDR
For women aged 30 years and older in routine clinical practice who are negative by co-testing (both HPV and cytology), 3-year screening intervals were safe because a single negative test for HPV was sufficient to reassure against cervical cancer over 5 years.
...
1
2
3
4
5
...